Scancell (LON:SCLP) Trading 7% Higher After Insider Buying Activity

Scancell Holdings plc (LON:SCLP) rose 7% during trading on Thursday after an insider bought additional shares in the company. The stock traded as high as GBX 10.43 ($0.14) and last traded at GBX 9.90 ($0.13). Approximately 1,065,551 shares were traded during mid-day trading, an increase of 21% from the average daily volume of 878,498 shares. The stock had previously closed at GBX 9.25 ($0.13).

Specifically, insider Martin Diggle bought 44,944 shares of Scancell stock in a transaction on Tuesday, May 20th. The stock was acquired at an average cost of GBX 9 ($0.12) per share, with a total value of £4,044.96 ($5,475.78).

Scancell Trading Down 1.0%

The firm has a market capitalization of £102.54 million, a PE ratio of -15.18 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The stock’s fifty day simple moving average is GBX 9.41 and its 200 day simple moving average is GBX 10.19.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.